BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Vr Laboratories Selects Hsg2001 as Lead Development Candidate for Candida Albicans Program


11/19/2012 10:12:51 AM

Bonita Springs, Fla., Nov. 16, 2012 /PRNewswire-iReach/ -- VR Laboratories LLC today announced they have selected a lead product candidate based on preclinical activity to target Candida albicans (C. albicans).C. albicans is the most common yeast species that causes candidiasis, commonly referred to as yeast infections. Candidiasis includes topical infections such as thrush as well as systemic and potentially life-threatening invasive diseases.

(Photo: http://photos.prnewswire.com/prnh/20121116/CG15396)

Three of every four women experience at least one bout of candidiasis in their lifetime and many experience recurrent infections. Symptoms of candidiasis vary depending on the area of the body that is infected. Candidiasis can be severe and causes more fatalities than any other systemic fungal infection. Candida species are the most common cause of fungal infections in immunocompromised patients such as cancer, AIDS, and transplant patients.

HSG2001 is an orally administered and bioavailable product that prevents the growth of C. albicansin vitro. Preclinical data suggests the product could be used alone or in combination with known antifungals.

"We searched our industry leading natural product library and identified HSG2001 as our lead candidate based on its ability to inhibit C. albicans growth in early stage testing." said Jeff Kottkamp, CEO of VR Laboratories. "We are very excited to expand the utilization of our knowledge and proprietary technology into discovering potential natural medicines for diseases with high unmet medical needs."

About VR Laboratories

VR Laboratories is an innovative natural products company formed by industry professionals in 2010 to be the leading global formulator and producer of natural products. VR Laboratories utilizes industry-changing proprietary technology to create, produce and market "First in Class" condition specific botanical based consumer health and wellness products, FDA-approved botanical pharmaceuticals and medicines, and proprietary ingredients for medicinal and functional foods and beverages. The company utilizes a proprietary technology platform created by HerbalScience, which has fully developed more than 1,000 medicinal and functional ingredients. VR Laboratories is headquartered in Bonita Springs, Florida.

SOURCE VR Laboratories www.vr-laboratories.com

Key Words: VR laboratories, Jeff Kottkamp, botanical, c. albicans, medicines, pharmaceuticals, natural, yeast infection

Media Contact:Jeff Kottkamp, CEO VR Laboratories, LLC, 239-597-9878, Jeffkottkamp@vr-laboratories.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE VR Laboratories LLC



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES